Prana Biotechnology Investor Presentation

June 27, 2018 Kerry Rowe

1_Prana Biotechnology Investor Presentation_2018-0627 final

Prana to commence Phase 1 clinical trial of PBT434 for treatment of parkinsonian diseases

First volunteers dosed in Phase I clinical trial of PBT434, Prana’s lead therapy for parkinsonian diseases

Prana’s Huntington Disease trial analysis to feature at global movement disorder conference

June 22, 2016

Quarterly Cash Flow Report

August 1, 2019August 1, 2019

Prana Announces that New York Academy of Sciences eBriefing available online

July 17, 2013

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Therapies
The Science
About us
Investors
News
Contact us

Careers
Privacy Policy

Prana Biotechnology Investor Presentation

Related Posts

Prana’s Huntington Disease trial analysis to feature at global movement disorder conference

Quarterly Cash Flow Report

Prana Announces that New York Academy of Sciences eBriefing available online